Claudia I Henschke, PhD, MD Email Claudia Henschke
- CLINICAL PROFESSOR | Diagnostic, Molecular and Interventional Radiology
- Hospital Affiliations
- Mount Sinai Brooklyn
- Mount Sinai Beth Israel
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
- ELCAP (Early Lung & Cardiac Screening Program) 212-241-2821 212-241-2821
Claudia I. Henschke, PhD, MD is Radiologist and Professor of Radiology.
Dr. Henschke is a pioneer and leading expert in diagnostic radiology with more than 25 years of clinical and research experience with low-dose CT screening; and she has led the implementation of numerous city, state, national, and international lung screening programs.
Since the start, in 1992, of the Early Lung Cancer Action Project (ELCAP) Dr. Henschke has worked on advancing the CT screening research of early lung disease, with a particular focus on lung cancer. ELCAP soon grew into an international program (I-ELCAP), and now she leads a collaborative and international group of distinguished physicians and scientists whose 75 institutions have, to date, screened over 79,000 people in 10 countries around the world for I-ELCAP.
In addition, the success of the I-ELCAP program led to another multi-national study, The Initiative for Early Lung Cancer Research on Treatment (IELCART), implemented in 2016 to assess the efficacy of various early lung cancer treatments.
Dr. Henschke has authored over 400 peer-reviewed publications, two books, many scientific presentations, and has trained over 80 physician researchers.
EDUCATION: PhD: University of Georgia; MD: Howard University; BA & MS: Southern Methodist University. Prior to joining the Icahn School of Medicine at Mount Sinai in 2010, Henschke was a faculty member at the Harvard Medical School and the Weill Cornell Medical College.
LANGUAGES: English, German, French
American Board of Radiology
MD, Howard University Col. of Medicine
Brigham and Women's Hospital, Harvard Medical School
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Henschke during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- Early Diagnosis And Treatment Research Foundation, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.